APA (7th ed.) Citation

Duan, H., Wang, Z., Cao, L., Zhu, Y., Tong, L., & Yan, X. (2024). A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer. Thoracic Cancer, 15(19), 1471. https://doi.org/10.1111/1759-7714.15312

Chicago Style (17th ed.) Citation

Duan, Hongtao, Zhaoyang Wang, Lili Cao, Yifang Zhu, Liping Tong, and Xiaolong Yan. "A Prospective Single‐center, Single‐arm, Open‐label, Phase II Study of Sintilimab and Anlotinib Combined with Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer." Thoracic Cancer 15, no. 19 (2024): 1471. https://doi.org/10.1111/1759-7714.15312.

MLA (9th ed.) Citation

Duan, Hongtao, et al. "A Prospective Single‐center, Single‐arm, Open‐label, Phase II Study of Sintilimab and Anlotinib Combined with Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer." Thoracic Cancer, vol. 15, no. 19, 2024, p. 1471, https://doi.org/10.1111/1759-7714.15312.